Duplex Enzymatic Recombinase Amplification Assay Coupled with Lateral Flow Dipstick for Rapid Identification of Methicillin-Resistant Staphylococcus aureus.

IF 3.8 2区医学 Q2 CHEMISTRY, MEDICINAL

ACS Infectious Diseases Pub Date : 2025-10-17 DOI:10.1021/acsinfecdis.5c00576

Arpasiri Srisrattakarn, Aroonwadee Chanawong, Orapan Sripichai, Jenjira Rujidamp, Neeranuch Maneenet, Nannapat Onsapiw, Thiwawan Bunleuhan, Aroonlug Lulitanond

{"title":"Duplex Enzymatic Recombinase Amplification Assay Coupled with Lateral Flow Dipstick for Rapid Identification of Methicillin-Resistant Staphylococcus aureus.","authors":"Arpasiri Srisrattakarn, Aroonwadee Chanawong, Orapan Sripichai, Jenjira Rujidamp, Neeranuch Maneenet, Nannapat Onsapiw, Thiwawan Bunleuhan, Aroonlug Lulitanond","doi":"10.1021/acsinfecdis.5c00576","DOIUrl":null,"url":null,"abstract":"46 clinical isolates, 28 nuc-carrying and 18 nuc-negative isolates, and 23 mecA-carrying and 23 mecA-negative isolates were subjected to a developed duplex isothermal enzymatic recombinase amplification assay accompanied by a lateral flow assay (ERA-LFA) method for methicillin-resistant Staphylococcus aureus (MRSA) detection. Additionally, 57 positive blood culture samples from patients were evaluated for preliminary testing. The sensitivity and specificity among the 46 clinical samples were 100% (28/28) and 88.9% (16/18), respectively, for nuc detection, and 100.0% (23/23 and 23/23) for mecA detection. For the 57 positive blood culture bottles, the ERA-LFA provided 100.0% (34/34) sensitivity and 95.7% (22/23) specificity for nuc detection and 96.5% specificity (55/57) for mecA detection. The detection limits of the ERA-LFA for the nuc and mecA genes were 1 and 10 CFU/reaction, respectively.","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.5c00576","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

46 clinical isolates, 28 nuc-carrying and 18 nuc-negative isolates, and 23 mecA-carrying and 23 mecA-negative isolates were subjected to a developed duplex isothermal enzymatic recombinase amplification assay accompanied by a lateral flow assay (ERA-LFA) method for methicillin-resistant Staphylococcus aureus (MRSA) detection. Additionally, 57 positive blood culture samples from patients were evaluated for preliminary testing. The sensitivity and specificity among the 46 clinical samples were 100% (28/28) and 88.9% (16/18), respectively, for nuc detection, and 100.0% (23/23 and 23/23) for mecA detection. For the 57 positive blood culture bottles, the ERA-LFA provided 100.0% (34/34) sensitivity and 95.7% (22/23) specificity for nuc detection and 96.5% specificity (55/57) for mecA detection. The detection limits of the ERA-LFA for the nuc and mecA genes were 1 and 10 CFU/reaction, respectively.

查看原文本刊更多论文

双酶重组酶扩增法联合侧流试纸快速鉴定耐甲氧西林金黄色葡萄球菌。

采用双等温酶重组酶扩增法和横向流动法（ERA-LFA）检测耐甲氧西林金黄色葡萄球菌（MRSA），对46株临床分离株、28株携带nuc和18株阴性分离株、23株携带meca和23株meca阴性分离株进行检测。此外，对57例患者阳性血培养样本进行初步检测。46份临床样本中，nuc检测的敏感性为100%(28/28)，特异度为88.9% (16/18)，mecA检测的敏感性为100.0%（23/23和23/23）。对于57个阳性血培养瓶，ERA-LFA检测nuc的灵敏度为100.0%(34/34)，特异性为95.7%(22/23)，检测mecA的特异性为96.5%（55/57）。ERA-LFA对nuc和mecA基因的检出限分别为1和10 CFU/reaction。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES

CiteScore

9.70

自引率

3.80%

发文量

213

期刊介绍： ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.